SEP-363856: Ph II SEP361-201 started

Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. subsidiary began the double-blind, placebo-controlled, international Phase II SEP361-201 trial to evaluate 50 and 75 mg

Read the full 213 word article

User Sign In